A new meta‑analysis compared CAR‑T therapies with bispecific antibodies in relapsed or refractory indolent B‑cell non‑Hodgkin’s lymphoma, synthesizing efficacy and safety across published trials. The study aggregates response rates, durability, and adverse‑event profiles to help clinicians and developers weigh modality tradeoffs. Researchers performed cross‑trial comparisons and highlighted differences in response durability and toxicity patterns. The analysis provides a reference point for sponsor strategy, payers assessing relative value, and clinical teams choosing between cellular and bispecific approaches for difficult‑to‑treat B‑cell malignancies.